The BRITS set out to quantify the percentage of tumors that changed receptor status (positive to negative or negative to positive) for ER, PR, and HER2 expression between the original and recurrent tumor in women with breast cancer and to determine the proportion of patients in which a switch in ER, PR, or HER2 led to a change in the subsequent treatment plan. Here, ERBB2 is linked to neoplasm.